Table 3

 Cumulative major outcomes, quality adjusted life years lost, and costs expected over 10 years, the incremental cost per outcome for each screening strategy, and the average cost per outcome (compared to no screening) for each assumption about pelvic inflammatory disease (PID) progression: PID = 1%

Total MOTotal QALYs lostTotal cost (£)Incremental cost (£)/MOAIncremental cost (£)/QALY gainedAverage cost (£)/MOAAverage cost (£)/QALY gained
MO, major outcome; MOA, major outcomes averted. Values in the table are rounded for presentation. QALY, quality adjusted life years; All costs and effects are discounted at 3.5%. Results are presented in rank order of total costs, which include costs of infection, complications, and programme costs. Dominated means that the MOA or QALYs gained is less than the non-dominated strategy above it in the table.
Baseline, noscreening39310108 408––––
Strategy 1 <202566430 991236484 337236484 337
Strategy 2 <202225670 6807118241 2713305116 693
Strategy 3 <202015739 2673125149,7453284119 562
Strategy 1 <252155811 689DominatedDominated3960139 219
Strategy 1 <3020351 196 464DominatedDominated5754207 198
Strategy 2 <2517141 378 32821 573736 3875728206 685
Strategy 3 <2513731 494 8623474157 3045432201 371
Strategy 1 <3518941 577 516DominatedDominated7204262 845
Strategy 1 <4018541 959 279DominatedDominated8905326 900
Strategy 2 <3014932 088 871DominatedDominated8122296 053
Strategy 3 <3011432 253 12632 3741 544 5677696290 770
Strategy 2 <3514032 799 862DominatedDominated10 657389 895
Strategy 3 <3510423 015 80875 2083 161 80910 067381 688
Strategy 2 <4013333 517 839DominatedDominated13 157485 712
Strategy 3 <409423 773 36376 8416 909 37912 271474 314